BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES

被引：0
|
作者：
Foster, S. A. [1 ]
Milev, S. [2 ]
Hoog, M. [3 ]
Mason, O. [1 ]
Sardesai, A. [4 ]
Hasan, A. [1 ]
Marrone, C. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Evidera, San Francisco, CA USA
[3] Evidera, Bethesda, MD USA
[4] Evidera, St Laurent, PQ, Canada
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1313
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND40
引用
收藏
页码：S277 / S277
页数：1
相关论文
共 50 条
  • [31] Patient Gains in Daily Functioning and Reductions in Disability with Galcanezumab among Patients with Episodic and Chronic Migraine
    Ruff, Dustin
    Ford, Janet
    Starling, Amaal
    Detke, Holland C.
    Nichols, Russell
    Port, Martha
    Aurora, Sheena K.
    NEUROLOGY, 2019, 92 (15)
  • [32] Patient Gains in Daily Functioning and Reductions in Disability with Galcanezumab Among Patients with Episodic and Chronic Migraine
    Ruff, D.
    Ford, J.
    Starling, A. J.
    Detke, H. C.
    Nichols, R.
    Port, M.
    Aurora, S. K.
    HEADACHE, 2019, 59 : 101 - 101
  • [33] Sustained Reduction of Migraine Headache Days in Patients with Episodic Migraine During Months 4 to 6 of Treatment with Galcanezumab
    Tepper, Stewart J.
    Ruff, Dustin
    Wietecha, Linda
    NEUROLOGY, 2020, 94 (15)
  • [34] SHIFT FROM CHRONIC TO EPISODIC MIGRAINE STATUS AND HIGH- TO LOW-FREQUENCY EPISODIC MIGRAINE STATUS AMONG PATIENTS WITH TREATMENT-RESISTANT MIGRAINE IN A PHASE 3 GALCANEZUMAB STUDY
    Day, Kathleen A.
    Rettiganti, Mallik
    Ferguson, Margaret B.
    Stroud, Chad E.
    Trewin, Benjamin P.
    Takeshima, Takao
    Kingston, William S.
    CEPHALALGIA, 2020, 40 : 75 - 75
  • [35] Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine
    Yang, Chun-Pai
    Lee, Chia-Fang
    Dell'Agnello, Grazia
    Hundemer, Hans-Peter
    Lipsius, Sarah
    Wang, Shuu-Jiun
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (10) : 1653 - 1666
  • [36] Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
    Pozo-Rosich, Patricia
    Samaan, Karen H.
    Schwedt, Todd J.
    Nicholson, Robert A.
    Rettiganti, Mallikarjuna
    Pearlman, Eric M.
    ADVANCES IN THERAPY, 2021, 38 (06) : 3154 - 3165
  • [37] Safety and efficacy of galcanezumab in chronic and episodic migraine patients: a systematic review and meta-analysis of randomized controlled trials
    Zaazouee, Mohamed Sayed
    Ebrahim, Rokaya Y.
    Al-araj, Ghaida'a
    Zaki, Ibram
    Saad, Ahmed
    Farhat, Abdullah Mohamed
    Ali, Mustafa Hussein
    Elshennawy, Mohamed
    Fawy, Omar Khaled Fahmy
    Ahmed, Hadi F.
    Alahmad, Ziad
    Nada, Eman Ayman
    Abo-Hamra, Reem I.
    Elsnhory, Ahmed Bostamy
    Eleyan, Mohammed
    AbuEl-Enien, Hazem
    Elromely, Rasha Abdo
    AbdelQadir, Yossef Hassan
    Shah, Jaffer
    Elshanbary, Alaa Ahmed
    EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2024, 60 (01):
  • [38] Sustained Reduction of Migraine Headache Days in Patients With Episodic Migraine During Months 4 to 6 of Treatment With Galcanezumab
    Ferrari, Michel D.
    Tepper, Stewart J.
    Ruff, Dustin
    Wietecha, Linda
    CEPHALALGIA, 2019, 39 : 217 - 217
  • [39] Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
    Patricia Pozo-Rosich
    Karen H. Samaan
    Todd J. Schwedt
    Robert A. Nicholson
    Mallikarjuna Rettiganti
    Eric M. Pearlman
    Advances in Therapy, 2021, 38 : 3154 - 3165
  • [40] BUDGET IMPACT OF INTRAVENOUS EPTINEZUMAB IN THE PREVENTION OF CHRONIC MIGRAINE PATIENTS IN UNITED ARAB EMIRATES
    Elattar, M.
    Zidan, T.
    Saeed, S.
    Elsisi, G.
    VALUE IN HEALTH, 2024, 27 (12)
12345